🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05830136
Recruiting Not applicable

Application of Sodium Bicarbonate Ringer's Solution in Laparoscopic Hepatectomy

NCT05830136 · tracked via the Priya Life Science China tracker
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Not applicable
Started
2022-02-01
Last updated
2024-11-12

Condition(s) studied

Hepatic Ischemia

Investigational drug(s) / intervention(s)

sodium bicarbonate Ringer's solution

sodium bicarbonate Ringer's solution: Sodium bicarbonate Ringer's solution was used in Group A as intraoperative intravenous fluids. Lactate Ringer's solution was used in Group B as intraoperative intravenous fluids.

Study summary

Compared the effects of Sodium bicarbonate Ringer's solution and lactate Ringer's solution on the internal environment and hemodynamics of patients during laparoscopic liver resection, to observe the application prospect of sodium bicarbonate Ringer's solution in Laparoscopic hepatectomy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. ≥18 years old, 2. patients who plan to undergoing laparoscopic hepatectomy ; 3. Willing to sign informed consent. Exclusion Criteria: 1. age \<18 years 2. pregnancy 3. active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, history of congestive heart failure) 4. history of significant cerebrovascular disease 5. restrictive or obstructive pulmonary disease 6. uncontrolled hypertension 7. renal dysfunction (glomerular filtration rate \<60 mL/min), 8. evidence of hepatic metabolic disorder (bilirubin \>35 mmol/L) 9. presence of active infection

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shijiang Liu Nanjing Jiangsu Recruiting

More The First Affiliated Hospital with Nanjing Medical University trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05830136 on ClinicalTrials.gov ↗ ← All trials in China